secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALVELLA THERAPEUTICS, INC. (PVLA)
CIK:        0001583648
Form:       8-K
Filed at:   2026-10-28T11:30:13+00:00
Accession:  0001193125-26-435113
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

FDA accepts Palvella's QTORIN rapamycin NDA with Priority Review; PDUFA date Feb 28, 2027
--------------------------------------------------------------------------------

- FDA accepted for filing and granted Priority Review to the NDA for QTORIN 3.9% rapamycin anhydrous gel in microcystic lymphatic malformations.
- PDUFA target action date set for February 28, 2027; if approved, would be the first FDA-approved therapy for microcystic LMs (>30,000 diagnosed in U.S.).
- Phase 3 SELVA met all six prespecified endpoints (all p<0.001); 95% of participants aged 6+ completing evaluation improved on the mLM-IGA primary endpoint.
- No drug-related serious adverse events in SELVA; systemic rapamycin concentrations below 2 ng/mL at all measured timepoints.
- Palvella is preparing a standalone U.S. commercial launch in the first half of 2027; also advancing QTORIN rapamycin in venous malformations and angiokeratomas.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583648/000119312526435113/0001193125-26-435113-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583648/000119312526435113/pvla-20261028.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-435113

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer